ConcertAI Launches ACT Platform to Transform Clinical Trials with End-to-End Agentic AI Intelligence
Published: 03 Feb 2026
Author: Precedence Research
ConcertAI, an established developer of oncology real-world evidence and AI-based software platforms, has announced the release of Accelerated Clinical Trials (ACT). This is a new-generation enterprise agentic artificial intelligence platform that will radically transform the process of planning, executing, and optimizing clinical trials. ACT is a significant advance in the application of predictive and automated intelligence through the full clinical development life cycle.
The foundational aspect of ACT is CARAai, the proprietary agentic AI platform of ConcertAI that coordinates a system of specialized AI agents with the ability to reason and perform autonomous tasks. The agents are intended to aid the key clinical trial operations, such as literature synthesis, protocol development, competitive environment research, feasibility modelling, location recognition, and patienttrial matching. Trial teams no longer need to use disconnected tools or manual analysis. They can now have a single intelligence layer to constantly assess the probability of a particular event, identify risks at an early stage, and prescribe data-driven actions throughout the study lifecycle. This enables sponsors are able to develop trials with a greater chance of achieving enrollment objectives and regulatory endpoints at the beginning.
The intelligence of the platform is further developed with the connections to authoritative data, including PubMed and ClinicalTrials.gov, and proprietary oncology-specific real-world datasets maintained by ConcertAI. Such a multimodal data basis enables the agents of ACT to learn continuously as the results of current tests, experience, and new scientific findings develop. This direction has attracted the attention of industry analysts, with Frost & Sullivan making ConcertAI one of its top AI clinical trial automation solutions by 2026. Furthermore, in addition to efficiency and cost-cutting, ACT has the potential to be used as a strategic facilitator of innovation in life sciences.
Executive Statement
Eron Kelly, Chief Executive Officer of ConcertAI, emphasized the broader impact of the platform, stating, “Clinical trial inefficiencies come at an enormous cost-not just financially, but for patients who are waiting for new therapies. Sponsors don’t need another isolated point solution; they need an integrated, end-to-end system that can anticipate challenges and guide smarter decisions. With ACT, we are delivering on the promise of agentic AI for life sciences, providing trial teams with unprecedented visibility, control, and predictive insight across the entire study lifecycle.”